Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
$0.54
$0.70
$0.50
$1.95
$5.81M1.6220,818 shs271 shs
bioAffinity Technologies, Inc. stock logo
BIAF
bioAffinity Technologies
$2.45
-5.4%
$2.16
$0.95
$3.62
$28.20M3.93183,430 shs112,523 shs
iSpecimen Inc. stock logo
ISPC
iSpecimen
$0.28
-6.7%
$0.34
$0.20
$1.89
$2.60M1.69679,956 shs281,532 shs
Novo Integrated Sciences, Inc. stock logo
NVOS
Novo Integrated Sciences
$0.53
+1.9%
$0.57
$0.42
$5.38
$10.01M-1.78708,450 shs533,440 shs
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
0.00%-16.34%-14.29%-10.00%-56.45%
bioAffinity Technologies, Inc. stock logo
BIAF
bioAffinity Technologies
-5.41%-15.81%+15.57%+53.13%+19.51%
iSpecimen Inc. stock logo
ISPC
iSpecimen
-5.86%+30.42%+10.55%-40.89%-83.16%
Novo Integrated Sciences, Inc. stock logo
NVOS
Novo Integrated Sciences
+1.94%+2.94%+8.72%-25.78%-51.34%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
bioAffinity Technologies, Inc. stock logo
BIAF
bioAffinity Technologies
N/AN/AN/AN/AN/AN/AN/AN/A
iSpecimen Inc. stock logo
ISPC
iSpecimen
N/AN/AN/AN/AN/AN/AN/AN/A
Novo Integrated Sciences, Inc. stock logo
NVOS
Novo Integrated Sciences
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
2.00
HoldN/AN/A
bioAffinity Technologies, Inc. stock logo
BIAF
bioAffinity Technologies
N/AN/AN/AN/A
iSpecimen Inc. stock logo
ISPC
iSpecimen
N/AN/AN/AN/A
Novo Integrated Sciences, Inc. stock logo
NVOS
Novo Integrated Sciences
N/AN/AN/AN/A

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
$10K580.50N/AN/A($2.27) per share-0.24
bioAffinity Technologies, Inc. stock logo
BIAF
bioAffinity Technologies
$2.53M11.15N/AN/A$0.51 per share4.80
iSpecimen Inc. stock logo
ISPC
iSpecimen
$9.93M0.26N/AN/A$1.07 per share0.26
Novo Integrated Sciences, Inc. stock logo
NVOS
Novo Integrated Sciences
$12.57M0.80N/AN/A$1.15 per share0.46

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
-$48.07M-$7.98N/AN/AN/A-3,967.23%-339.10%5/21/2024 (Estimated)
bioAffinity Technologies, Inc. stock logo
BIAF
bioAffinity Technologies
-$7.94M-$0.90N/AN/A-313.34%-107.20%-84.10%5/20/2024 (Estimated)
iSpecimen Inc. stock logo
ISPC
iSpecimen
-$11.10M-$1.23N/AN/A-111.81%-80.37%-61.99%5/2/2024 (Estimated)
Novo Integrated Sciences, Inc. stock logo
NVOS
Novo Integrated Sciences
-$13.22MN/A0.00N/A-88.48%-50.54%-33.80%7/15/2024 (Estimated)

Latest BIAF, ISPC, ADXS, and NVOS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/1/2024Q4 2023
bioAffinity Technologies, Inc. stock logo
BIAF
bioAffinity Technologies
N/A-$0.26-$0.26-$0.26N/A$2.21 million
3/13/2024Q4 2023
iSpecimen Inc. stock logo
ISPC
iSpecimen
N/A-$0.34-$0.34-$0.34N/A$2.58 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
N/AN/AN/AN/AN/A
bioAffinity Technologies, Inc. stock logo
BIAF
bioAffinity Technologies
N/AN/AN/AN/AN/A
iSpecimen Inc. stock logo
ISPC
iSpecimen
N/AN/AN/AN/AN/A
Novo Integrated Sciences, Inc. stock logo
NVOS
Novo Integrated Sciences
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
N/A
0.30
0.30
bioAffinity Technologies, Inc. stock logo
BIAF
bioAffinity Technologies
0.17
1.77
1.76
iSpecimen Inc. stock logo
ISPC
iSpecimen
N/A
1.36
1.36
Novo Integrated Sciences, Inc. stock logo
NVOS
Novo Integrated Sciences
N/A
0.50
0.41

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
7.18%
bioAffinity Technologies, Inc. stock logo
BIAF
bioAffinity Technologies
1.64%
iSpecimen Inc. stock logo
ISPC
iSpecimen
13.62%
Novo Integrated Sciences, Inc. stock logo
NVOS
Novo Integrated Sciences
5.67%

Insider Ownership

CompanyInsider Ownership
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
0.63%
bioAffinity Technologies, Inc. stock logo
BIAF
bioAffinity Technologies
44.30%
iSpecimen Inc. stock logo
ISPC
iSpecimen
32.70%
Novo Integrated Sciences, Inc. stock logo
NVOS
Novo Integrated Sciences
10.90%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
N/A10.75 million10.68 millionNot Optionable
bioAffinity Technologies, Inc. stock logo
BIAF
bioAffinity Technologies
1411.51 million6.41 millionNot Optionable
iSpecimen Inc. stock logo
ISPC
iSpecimen
539.37 million6.31 millionNot Optionable
Novo Integrated Sciences, Inc. stock logo
NVOS
Novo Integrated Sciences
12719.06 million16.98 millionNot Optionable

BIAF, ISPC, ADXS, and NVOS Headlines

SourceHeadline
Novo Integrated Sciences Reports Fiscal Year 2024 Second Quarter Financial ResultsNovo Integrated Sciences Reports Fiscal Year 2024 Second Quarter Financial Results
businesswire.com - April 15 at 4:30 PM
Novo Integrated Sciences Closes on $6,210,000 Securities Purchase AgreementNovo Integrated Sciences Closes on $6,210,000 Securities Purchase Agreement
businesswire.com - April 11 at 5:00 PM
Novo Integrated Sciences Provides Update on Certain Current Actions and EventsNovo Integrated Sciences Provides Update on Certain Current Actions and Events
businesswire.com - March 26 at 2:30 PM
Novo Integrated Sciences Inc NVOSNovo Integrated Sciences Inc NVOS
morningstar.com - March 22 at 11:50 PM
Novo Integrated Sciences Inc (NVOS)Novo Integrated Sciences Inc (NVOS)
uk.investing.com - February 23 at 1:24 AM
Novo Integrated Sciences Stock (NASDAQ:NVOS), Short Interest ReportNovo Integrated Sciences Stock (NASDAQ:NVOS), Short Interest Report
benzinga.com - February 22 at 10:21 AM
Novo Integrated Sciences Subsidiary, Clinical Consultants International, Signs Agreement with Futura Surgicare Pvt Ltd.Novo Integrated Sciences Subsidiary, Clinical Consultants International, Signs Agreement with Futura Surgicare Pvt Ltd.
finance.yahoo.com - February 21 at 6:47 PM
Novo Integrated Sciences Subsidiary, Clinical Consultants International, Signs Agreement with Futura Surgicare Pvt Ltd.Novo Integrated Sciences Subsidiary, Clinical Consultants International, Signs Agreement with Futura Surgicare Pvt Ltd.
businesswire.com - February 21 at 4:05 PM
Novo Integrated Sciences Receives Limited Waiver to Securities Purchase Agreement for $70,000,000 Promissory NoteNovo Integrated Sciences Receives Limited Waiver to Securities Purchase Agreement for $70,000,000 Promissory Note
finance.yahoo.com - February 20 at 5:40 PM
Novo Integrated Sciences Receives Limited Waiver to Securities Purchase Agreement for $70,000,000 Promissory NoteNovo Integrated Sciences Receives Limited Waiver to Securities Purchase Agreement for $70,000,000 Promissory Note
businesswire.com - February 20 at 2:00 PM
Novo Integrated Sciences Appoints New PresidentNovo Integrated Sciences Appoints New President
finance.yahoo.com - February 16 at 6:27 PM
Novo Integrated Sciences Appoints New PresidentNovo Integrated Sciences Appoints New President
businesswire.com - February 16 at 2:00 PM
Novo Integrated Sciences Reports Fiscal Year 2024 First Quarter Financial ResultsNovo Integrated Sciences Reports Fiscal Year 2024 First Quarter Financial Results
finance.yahoo.com - January 22 at 9:27 PM
Psychocare Health Pvt Ltd Announces Strategic Collaboration with Novo Integrated Sciences to Introduce Innovative Healthcare Solutions GloballyPsychocare Health Pvt Ltd Announces Strategic Collaboration with Novo Integrated Sciences to Introduce Innovative Healthcare Solutions Globally
theprint.in - January 11 at 8:57 AM
Blacksheep Trust Files Partial Assignment of $1 Billion Dollar Gold Backed Bond to Novo Integrated SciencesBlacksheep Trust Files Partial Assignment of $1 Billion Dollar Gold Backed Bond to Novo Integrated Sciences
finance.yahoo.com - December 19 at 6:42 PM
NVOS Stock Earnings: Novo Integrated Sciences Reported Results for Q4 2023NVOS Stock Earnings: Novo Integrated Sciences Reported Results for Q4 2023
investorplace.com - December 15 at 12:01 AM
Novo Integrated Sciences Reports 2023 Fiscal Year Financial ResultsNovo Integrated Sciences Reports 2023 Fiscal Year Financial Results
finance.yahoo.com - December 14 at 7:33 PM
Novo Integrated Sciences $60M Acquisition of Ophir Collection Gets Court ApprovalNovo Integrated Sciences $60M Acquisition of Ophir Collection Gets Court Approval
marketwatch.com - December 5 at 3:38 PM
Novo Integrated Sciences’ Purchase and Sale Agreement to Acquire Ophir Collection Receives Court ApprovalNovo Integrated Sciences’ Purchase and Sale Agreement to Acquire Ophir Collection Receives Court Approval
finance.yahoo.com - December 4 at 3:53 PM
Novo Integrated Sciences: Regulation Fd Disclosure, Other Events, Financial Statements And ExhibitsNovo Integrated Sciences: Regulation Fd Disclosure, Other Events, Financial Statements And Exhibits
cbonds.com - November 27 at 8:46 AM
Novo Integrated Sciences Regains Compliance with Nasdaq Minimum Bid Price RequirementNovo Integrated Sciences Regains Compliance with Nasdaq Minimum Bid Price Requirement
finance.yahoo.com - November 24 at 12:33 PM
Novo Integrated Sciences: Regulation Fd Disclosure, Financial Statements And ExhibitsNovo Integrated Sciences: Regulation Fd Disclosure, Financial Statements And Exhibits
cbonds.com - November 8 at 8:26 AM
Novo Integrated Sci (NASDAQ: NVOS) down 54% - we told you it was a dog, a disasterNovo Integrated Sci (NASDAQ: NVOS) down 54% - we told you it was a dog, a disaster
dhakatribune.com - November 7 at 10:42 AM
Novo Integrated Sciences stock plunges 54% amid stock split, debt updateNovo Integrated Sciences stock plunges 54% amid stock split, debt update
msn.com - November 6 at 5:08 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Ayala Pharmaceuticals logo

Ayala Pharmaceuticals

NASDAQ:ADXS
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.
bioAffinity Technologies logo

bioAffinity Technologies

NASDAQ:BIAF
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.
iSpecimen logo

iSpecimen

NASDAQ:ISPC
iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, clinics, private practice groups, laboratories, blood centers, biobanks, clinical research sites, and cadaveric donation centers. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. iSpecimen Inc. was incorporated in 2009 and is headquartered in Lexington, Massachusetts.
Novo Integrated Sciences logo

Novo Integrated Sciences

NASDAQ:NVOS
Novo Integrated Sciences, Inc., together with its subsidiaries, provides multidisciplinary primary care and related wellness products and services in Canada. It operates through two segments, Healthcare Services and Product Sales. The company offers physiotherapy, chiropractic care, manual/manipulative therapy, occupational therapy, eldercare, massage therapy, acupuncture and functional dry needling, chiropody, stroke and traumatic brain injury/neurological rehabilitation, kinesiology, vestibular therapy, concussion management and baseline testing, trauma sensitive yoga and meditation for concussion-acquired brain injury and occupational stress-PTSD, women's pelvic health program, sports medicine therapy, assistive devices, dietitian, holistic nutrition, fall prevention education, sports team conditioning program, and private personal training services. It also engages in the assessment, diagnosis, treatment, pain management, rehabilitation, education, and prevention of various orthopedic, musculoskeletal, sports injury, and neurological conditions across various demographics, including pediatric, adult, and geriatric populations. In addition, the company offers eldercare physiotherapy services, such as long-term care homes, retirement homes, community-based home care physiotherapy, community-based group exercise classes and fall prevention programs, and community-based outpatient clinics; and elderly occupational therapy services for retirement homes and community, and long-term care sectors. Further, it provides medical technology services, such as telemedicine and remote patient monitoring; develops and distributes personalized health and wellness product solutions; and operates corporate-owned clinics. The company was formerly known as Turbine Truck Engines, Inc. and changed its name to Nova Integrated Sciences, Inc. in July 2017. The company is headquartered in Bellevue, Washington. Novo Integrated Sciences, Inc. is a subsidiary of ALMC-ASAP Holdings, Inc.